FDA to Use Entelos' In Silico Modeling Software to Assess Cardiovascular Drugs | GenomeWeb
NEW YORK (GenomeWeb News) — The US Food and Drug Administration will use Entelos’ computer modeling software to assess the safety and efficacy of a specific set of cardiovascular drugs, the company said today.
 
Under the agreement, FDA will use the company’s Cardiovascular PhysioLab, which is a large-scale computer simulation of cholesterol regulation, atherogenesis, and cardiovascular risk. The Foster City, Calif.-based firm would not disclose the compound class and drug set that will be evaluated.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.